Annual report pursuant to Section 13 and 15(d)

Revenue (Details)

v3.22.0.1
Revenue (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended 27 Months Ended
Jul. 01, 2021
Aug. 31, 2017
Dec. 31, 2021
Sep. 30, 2021
Sep. 30, 2022
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2024
Disaggregation of Revenue [Line Items]                
Revenues           $ 5,398 $ 6,699  
Discontinued Operations, Disposed of by Sale | Pediatric Portfolio                
Disaggregation of Revenue [Line Items]                
other long-term assets     $ 4,300     4,300    
Other receivables     1,000     1,000    
Amount received           2,200    
Scenario, Forecast | Discontinued Operations, Disposed of by Sale | Pediatric Portfolio                
Disaggregation of Revenue [Line Items]                
Proceeds from divestiture of businesses         $ 2,000     $ 1,000
Product revenue, net                
Disaggregation of Revenue [Line Items]                
Revenues           4,773 6,699  
Millipred | Teva Pharmaceutical Industries Ltd.                
Disaggregation of Revenue [Line Items]                
Percent of net profit for installment payments       50.00%        
Installment payments $ 500              
Royalty expense     $ 1,000          
License revenue                
Disaggregation of Revenue [Line Items]                
Revenues   $ 25,000       $ 625 $ 0  
Major Customer Number One | Sales Revenue | Customer Concentration Risk                
Disaggregation of Revenue [Line Items]                
Concentration risk percentage           63.00% 46.00%  
Major Customer Number Two | Sales Revenue | Customer Concentration Risk                
Disaggregation of Revenue [Line Items]                
Concentration risk percentage           21.00% 25.00%  
Major Customer Number Three | Sales Revenue | Customer Concentration Risk                
Disaggregation of Revenue [Line Items]                
Concentration risk percentage           16.00% 27.00%